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Note
HIPAA-Cratic or HIPAA-Critical: U.S. Privacy
Protections Should Be Guaranteed By Covered
Entities Working Abroad
Grace Fleming*
Privacy is a threatened right. Phone calls, emails, and even
the conversations of heads of state are no longer reliably pri1
vate. Health and medical histories contain some of our most
personal and sensitive information and privacy in this realm is
of paramount importance. Privacy concerns in health care and
medical research are intensified by the growth of electronic
2
medical records and the rise of the Internet. At the touch of a
button, information can be transferred around the globe. Therefore, it is no surprise that privacy issues have dominated health
3
information discussions in the last half-century. The Health
Insurance Portability and Accountability Act (HIPAA) is designed to address these privacy issues, but because approximately one-third of U.S.-based clinical trials are now conducted
4
outside of the United States, these protections may not extend
* J.D. Candidate 2014, University of Minnesota Law School; M.A. Candidate in Bioethics 2014, University of Minnesota; B.A. 2010, New York University. Thanks to Professor Amy Monahan for her guidance in writing this
Note. Thanks also to Gordon Apple for introducing me to this gray area in the
law. Sincere thanks to the editors and staff of the Minnesota Law Review for
their efforts and support in getting my Note to publication. Thanks to my parents, my sister, and my friends Nalle and Teddy for all their support during
Law School. Finally, thanks to the Produce Department at Red Owl Grocery.
Copyright © 2014 by Grace Fleming.
1. David E. Sanger & Mark Mazzetti, Allegation of U.S. Spying on Merkel Puts Obama at Crossroads, N.Y. TIMES, Oct. 24, 2013, http://www.nytimes
.com/2013/10/25/world/europe/allegation-of-us-spying-on-merkel-puts-obama
-at-crossroads.html.
2. See BARRY R. FURROW ET AL., LIABILITY AND QUALITY ISSUES IN
HEALTH CARE 259 (Thomson West, 6th ed. 2008).
3. See id. at 265.
4. See Seth W. Glickman et al., Ethical and Scientific Implications of the
Globalization of Clinical Research, 360 NEW ENG. J. MED. 816, 816 (2009).
This study used the online registry at ClinicalTrials.gov to look at recruitment
in industry-sponsored phase three clinical trials as of November 2007 for
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beyond U.S. borders. The globalization of research has triggered debates about researchers’ ethical obligations concerning
privacy among large research universities, non-profit organiza5
tions, and other U.S. entities covered by HIPAA. As the number of off-shore clinical trials grows, HIPAA must change to reflect this emerging globalized health and biomedical research
industry. To address the challenges of worldwide threats to
privacy and the growing importance of health information privacy to all people, U.S. entities must be required to follow
HIPAA, both at home and abroad.
In the United States, patients, providers, and researchers
are increasingly aware of the potential damage caused by a
6
breach of privacy. Such breaches have included medical rec7
ords improperly discarded in dumpsters, patients’ HIV status8
es revealed without patient consent, and private health rec9
ords sent to patients’ employers. Outside of the United States
privacy is also a growing issue. Leading up to the May 1, 2011
capture of Osama Bin Laden in Abbottabad, Pakistan, the Central Intelligence Agency (CIA) reportedly implemented a sham
campaign in which a physician went from house to house gathtwenty of the largest U.S.-based pharmaceutical companies. The study found
that around one third of the trials (157 of 509) were at that time conducted totally outside the United States and found that a majority of study sites (13,521
of 24,206) were also outside the United States. The authors wrote that many
of these trials were being conducted in developing countries.
5. See Carol Bova, Reframing the Influence of the Health Insurance Portability and Accountability Act on Research, 141 CHEST 782, 785 (2012); see also, e.g., International Research, DUKE UNIV. HEALTH SYS. HUM. RES. PROT.
PROGRAM (Aug. 3, 2011), http://irb.duhs.duke.edu/wysiwyg/downloads/41._
International_Research_5-31-2011_revision_8-3-2011.pdf.
6. See FURROW ET AL., supra note 2, at 268 (suggesting that concerns
about privacy in the health industry are a reality and consumers are increasingly vulnerable to breaches of their health information either deliberately or
accidentally that can come from either an external breach of security or within
the health care organization itself); Daniel J. Oates, Comment, HIPAA Hypocrisy and the Case for Enforcing Federal Privacy Standards Under State Law,
30 SEATTLE U. L. REV. 745, 745 (2006) (discussing a 1995 privacy catastrophe
where the daughter of a hospital employee took names and phone numbers
from medical records of recent emergency room patients and called falsely telling them they had contracted AIDS).
7. See, e.g., Jonathan Rodriguez, Private, Medical Information Left Out
in a Dumpster, WNCT9 (June 29, 2012), http://www.wnct.com/story/2101
30221/private-medical-information-left-out-in-a-dumpster.
8. See, e.g., Doe v. Medlantic Health Care Gr., Inc., 814 A.2d 939, 942
(D.C. Cir. 2003).
9. See Herman v. Kratche, No. 86697, 2006 WL 3240680, at *1 (Ohio Ct.
App. 2006).
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ering DNA under the guise of giving vaccinations. This blatant violation of patient privacy, wherein a physician collected
patient DNA without consent and gave it to the CIA, negatively
reflects on the entire medical profession—from physicians, to
researchers, to international humanitarian aid workers. The
mistrust fostered by such a breach inevitably hinders the aims
of improved global health, research, and international rela11
tions.
Congress passed the Health Insurance Portability and Accountability Act (HIPAA) in 1996 to provide standards for the
use, collection, and disclosure of Protected Health Information
12
(PHI). In the United States, HIPAA covers all information collected about patients by covered entities that falls under the
13
definition of PHI. This includes diagnoses, medical records,
14
and the patient’s address and phone number. Hospitals, physicians, third party payers, and staff all have a legal duty to
15
protect that information. The Department of Human Research
Protections (DHRP) in the U.S. Department of Health and
Human Services (HHS) has not provided guidance as to whether HIPAA’s requirements apply to research institutions, drug
and device companies, or any other U.S.-based research sponsor otherwise covered when conducting international clinical
trials. The Secretary of Health and Human Services Advisory
Committee on Human Research Protections asked the HHS to
develop and publish guidelines about HIPAA’s application in
international research, but as of 2013 this guidance has not
16
been produced. Beginning in the 1980s, clinical trials began
10. Les F. Roberts & Michael J. VanRooyen, Ensuring Public Health Neutrality, 368 NEW ENG. J. MED. 1073, 1073 (2013).
11. Id. at 1075.
12. 45 C.F.R. § 160.103 (2013) (“Health information means any information, whether oral or recorded in any form or medium, that: (1) Is created or
received by a health care provider, health plan, public health authority, employer, life insurer, school or university, or health care clearinghouse; and
(2) Relates to the past, present, or future physical or mental health or condition of an individual; the provision of health care to an individual; or the past,
present, or future payment for the provision of health care to an individual.”).
13. Protected Health Information is information that identifies, or could
be used to identify an individual and is created by a healthcare provider,
health plan, employer, or healthcare clearinghouse that relates to that individuals past, present, or future physical or mental health or payment for the
provision of healthcare. See id.
14. Id.
15. See 45 C.F.R. § 164.502(a) (2013).
16. See Secretary’s Advisory Committee on Human Research Protections
Appendix H, OFF. FOR HUM. RES. PROT., U.S. DEP’T OF HEALTH AND HUM.
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moving abroad because there are substantially fewer regulato17
ry requirements than those applicable in the United States.
This movement raises questions about the legal and ethical requirements for clinical researchers and research sponsors that
18
are based in the United States but working overseas.
This Note points out the holes in U.S. privacy laws governing the obligations of U.S.-covered entities performing research
abroad. It discusses the debate about HIPAA’s application outside the United States and concludes that HIPAA should apply
to U.S. entities working internationally. Part I provides a brief
background of HIPAA, including what it does and why it was
enacted. This background section then discusses current attempts to deal with the gray areas in this law and generally
explains the notion of standards of care in research. Part II analyzes barriers to implementing HIPAA overseas, discusses
how these barriers can be mitigated, and employs an ethical
argument in favor of the United States implementing HIPAA
abroad. Part III outlines governmental guidance that would
solve this ambiguity and guarantee privacy protections for all
human research subjects. It confronts practical barriers to implementation and explains that health information privacy is a
fundamental human right. HIPAA privacy protections are a
necessary part of all human subjects research in this increasingly global world and the government must respond to this
gap by expanding privacy protections.
I. AN INTRODUCTION TO HIPAA AND THE DEBATE ON
ITS APPLICATION ABROAD
HIPAA was the first federal rule to protect the privacy of
health information and guarantee patient access to that infor19
20
mation. HIPAA recognizes privacy as a fundamental right.
However, it is still unclear whether this right must be recognized by U.S. organizations when they work outside of the
21
country. Part A introduces HIPAA’s requirements and the
SERVS. (Jan. 6, 2014), http://www.hhs.gov/ohrp/sachrp/appendixh.html.
17. PETER BARTON HUTT ET AL., FOOD AND DRUG LAW 650 (Robert C.
Clark et al. eds., 3d ed. 2007).
18. See id. at 818–20; Eve M. Brunts et al., The International Clinical
Trials Roadmap: Steering Clear of Legal and Practical Roadblocks, J. HEALTH
& LIFE SCI. L., June 2012, at 1, 1; see also HUTT, supra note 17, at 650.
19. See FURROW ET AL., supra note 2, at 264.
20. Id.
21. See DEP’T OF HEALTH & HUM. SERVS., PROTECTING PERSONAL HEALTH
INFORMATION IN RESEARCH: UNDERSTANDING THE HIPAA PRIVACY RULE
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reasons for its enactment. Part B explains that the confusion
over HIPAA’s application abroad needs to be formally addressed, and that the confusion stems from its inconsistent application in current practice and the history of standards of
care abuse by U.S. research entities.
A. HIPAA’S HISTORY AND REQUIREMENTS
HIPAA was signed into law in 1996 in response to the expanding use of electronic health record technology and the increasing need for industry standardization in using electronic
22
health records. HIPAA was enacted to address this growing
use of electronic medical records and confront the many privacy
23
and security issues arising from electronic transactions.
1. HIPAA Basics: Who is Covered and What is Required
HIPAA covers three groups (“covered entities”): (1) health
plans, both individual and group plans that pay medical care
costs; (2) health care clearing houses, entities that process information such as billing companies and community health
management information systems; and (3) health care providers such as doctors, nurses, and therapists, and institutional
24
providers such as hospitals.
HIPAA has two parts: the Privacy Rule and the Security
Rule. The Privacy Rule applies to Protected Health Information
25
in all forms—oral, written, and electronic. The Privacy Rule
standardizes how and for what reasons a covered entity can
26
disclose a person’s PHI. It also outlines penalties for improper
27
disclosure and misuse. The Security Rule specifically address28
es the issues of electronic PHI. It mandates specific protections that covered entities must have for electronic medical rec(2003), [hereinafter DEP’T OF HEALTH & HUM. SERVS., UNDERSTANDING THE
PRIVACY RULE], available at http://privacyruleandresearch.nih.gov/pdf/
HIPAA_booklet_4-14-2003.pdf.
22. Young B. Choi et al., Challenges Associated with Privacy in Health
Care Industry: Implementation of HIPAA and the Security Rules, 30 J. MED.
SYS. 57, 58 (2006).
23. Id.
24. DEP’T OF HEALTH & HUM. SERVS., SUMMARY OF THE HIPAA PRIVACY
RULE, 2–3 (2003), available at http://www.hhs.gov/ocr/privacy/hipaa/
understanding/summary/privacysummary.pdf.
25. Id.
26. Id.
27. Id.
28. Choi, supra note 22, at 58.
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ords. These include administrative safeguards and physical
29
protections for computer systems and relevant facilities. The
Security Rule requires covered entities to monitor access to
PHI and lays out specific requirements concerning contracts
30
between covered entities and their business associates. In addition, the Security Rule requires that covered entities have
policies and procedures in place to ensure the health organiza31
tion’s compliance with HIPAA.
Not all researchers and research institutions in the United
32
States have to comply with HIPAA. However, a relationship
with a covered entity folds an otherwise not covered entity un33
der the jurisdiction of HIPAA. For example, researchers commonly rely on covered entities for funding or as sources of individually identifiable health information that is included in
34
research databases. In other instances, a researcher employed
by a covered entity may be bound by HIPAA in research en35
deavors undertaken as an employee. This coverage varies according to the relationship of the researcher or research initia36
tive to a covered entity.
2. How HIPAA Works and Who Enforces HIPAA
The Office for Civil Rights (OCR) at the U.S. Department
37
of Health and Human Services (HHS) enforces HIPAA. OCR
investigates complaints of HIPAA violations, performs audits of
covered entities, and does outreach and education to encourage
38
compliance. If there is a criminal violation, OCR works with
29. Id.
30. Id. A business associate is a person or organization, other than a covered entity’s workforce, that provides services to a covered entity or performs
certain functions on behalf of a covered entity and that work involves use or
disclosure of identifiable health information. Id. This is most often claims processing, data analysis, utilization review, or billing. Id.
31. Id.
32. See DEP’T OF HEALTH & HUM. SERVS., UNDERSTANDING THE PRIVACY
RULE supra note 21, at 1.
33. Id. at 6. For example, a University may be one legal entity that also
includes an academic medical center. That hospital within the University that
conducts covered activities, and the relationship it has with the University,
means that the entire University is subject to HIPAA. Id.
34. Id. at 1.
35. Id.
36. Id.
37. See Health Information Privacy, HHS.GOV, http://www.hhs.gov/ocr/
privacy/index.html (last visited Apr. 8, 2014).
38. See Health Information Privacy: Enforcement Process, HHS.GOV,
http://www.hhs.gov/ocr/privacy/hipaa/enforcement/
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the Department of Justice to enforce HIPAA. For the most
part, OCR works to achieve voluntary compliance through cor40
rective actions and agreements with covered entities. Civil
penalties are only imposed if the violation was willful, and penalties are not imposed if the compliance failure resulted from
reasonable cause and is rectified within a thirty-day grace peri41
od.
HIPAA is crucial to protecting patient privacy and contains
several requirements dedicated to achieving this goal. These
42
protections have been largely successful and long-standing.
The government should respond to the surge in international
research and ambiguity of HIPAA’s application abroad by expanding HIPAA protections to U.S. covered entities working
abroad.
B. HIPAA’S APPLICATION ABROAD: CONFUSION IN CURRENT
PRACTICES AND CURRENT APPROACHES TO STANDARDS OF CARE
HIPAA’s statutory language and ethical considerations
governing all human subject research has spurred debate
among researchers and scholars about whether HIPAA applies
43
internationally. The government has offered conflicting clues
on its approach to covered entities working abroad, resulting in
a patchwork application of privacy laws in the academic research community. One thing, however, is clear: privacy is now
expected in health settings.
1. Clues from HIPAA’s Text and Governmental Guidance
HHS has not explained, answered, or elaborated on
HIPAA’s application in international research settings.
HIPAA’s text and previous HHS guidelines do, however, provide some clues. HIPAA does not cover foreign national beneficiaries receiving healthcare from the Department of Defense
(DoD) or by any other federal agency or any agency acting on
process/index.html (last visited Apr. 8, 2014).
39. Id.
40. See FURROW ET AL., supra note 2, at 282.
41. Id.; see 45 C.F.R. § 160.401 (2013) (“Reasonable cause means an act or
omission in which a covered entity or business associate knew, or by exercising
reasonable diligence would have known, that the act or omission violated an
administrative simplification provision, but in which the covered entity or
business associate did not act with willful neglect.”).
42. Choi et al., supra note 22, at 58.
43. Bova, supra note 5, at 785.
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behalf of the DoD or federal agencies. This narrow exclusion,
combined with the broad definition of “individual” in the law
45
suggests that foreign nationals are otherwise covered. In addition, HIPAA focuses on covered entities and Protected Health
Information rather than the nationality of research partici46
pants. This has led some researchers and scholars to assume
47
that HIPAA does apply in international settings. International clinical trials can implicate the HIPAA Privacy Rule when
data is transferred to the United States and the investigator or
48
sponsor is a covered entity. Therefore, many researchers argue that HIPAA is not required in international research as
long as researchers de-identify data or never send the data
49
back to the covered entity in the United States. In 2004, however, a member of the Secretary’s Advisory Committee on Human Research Protection, Mark Barnes, noted that “there is
nothing in the rule that says it only applies to Americans or
American residents. It applies to all health information that’s
identifiable and that is handled by a covered entity, which
50
would include [researchers] who are abroad.”
The text and government statements do not definitively
answer whether HIPAA applies in international research settings, allowing arguments on both sides. Consequently, it is
necessary to consider the feasibility of applying HIPAA abroad
to determine prescribed practices for research entities. These
concerns ought to influence what kind of guidance the government should publish. Researchers currently face uncertainty,
and a response from the government is necessary.

44. Secretary’s Advisory Committee on Human Research Protections Appendix H, supra note 16.
45. Id. (defining individual as “the person who is the subject of protected
health information”); see 45 C.F.R. § 160.103 (2013).
46. DEP’T OF HEALTH & HUM. SERVS., UNDERSTANDING THE PRIVACY
RULE, supra note 21, at 1.
47. Secretary’s Advisory Committee on Human Research Protections Appendix H, supra note 16.
48. Eve M. Brunts, AHLA Seminar Materials J. Clinical Trials Update
AHLA-PAPERS P04250708 § VI. C. 1 (Apr. 25, 2007).
49. See, e.g., DUKE UNIV. HEALTH SYS. HUM. RES. PROT. PROGRAM, supra
note 5, at 1; HIPAA Authorization: International Language, JOHNS HOPKINS
MED. (Nov. 2010), http://www.hopkinsmedicine.org/institutional_review_
board/hipaa_research/hipaa_international_language.
50. Thompson To Hear Recommendations to Ease Researchers’ HIPAA
Concerns, FDA COMPLIANCE EXPERT (July 28, 2004), http://prod-admin1.tmg
.atex.cniweb.net:8080/preview/www/2.3427/2.3465/1.116184.
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2. Institutions of Higher Education Approach to HIPAA
Internationally Exemplifies the Patchwork of Compliance by
Covered Entities Abroad
Research programs at universities across the United States
apply HIPAA abroad in different ways, suggesting that the lack
of government clarification on this issue has important effects
on research and, as such, necessitates an immediate response.
For example, Duke University’s policy acknowledges that
whether HIPAA applies to international research is an unan51
swered question. It notes that once individually identifiable
information reaches U.S. soil under a covered entity like Duke,
52
it becomes subject to HIPAA protections. In addition to recognizing the debate over HIPAA’s application abroad, Duke’s policy also notes that it may be difficult to apply HIPAA in an in53
ternational setting. With this in mind, they offer researchers
the option of requesting that the Institutional Review Board
(IRB) approve modifications or waivers of HIPAA requirements
54
entirely.
Johns Hopkins takes a similar approach, requiring HIPAA
protections when international research data is transmitted to
55
a covered entity in the United States. Likewise, they suggest
that research teams in foreign countries may alter Johns Hopkins’ standard HIPAA privacy language requirements in con56
sent forms as long as they obtain IRB permission. IRBs offer
another check on the ethical practices of researchers and the
57
protection of research participants’ rights. Yale University
documents indicate that HIPAA may apply when conducting
international research if the information gathered is returned
58
to the University. The University recommends that data be
1.

51. DUKE UNIV. HEALTH SYS. HUM. RES. PROT. PROGRAM, supra note 5, at

52. Id.
53. Id.
54. Id.
55. JOHNS HOPKINS MED., supra note 49.
56. Id. This may be to respond to language or educational barriers. 21
C.F.R. § 56.102 (2013) (“Institutional Review Board (IRB) means any board,
committee, or other group formally designated by an institution to review, to
approve the initiation of, and to conduct periodic review of, biomedical research involving human subjects. The primary purpose of such review is to assure the protection of the rights and welfare of the human subjects.”).
57. 21 C.F.R. § 56.102 (2013).
58. Conducting Research Internationally, YALE UNIV. OFF. OF RES. ADMIN., http://researchadministration.yale.edu/ora-services/conducting-research
-internationally (last visited Apr. 8, 2014).
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de-identified before the investigator returns to Yale.
In contrast, the Human Research Protection Program at
University of California Los Angeles simply notes in its guidelines that HIPAA does not apply overseas or in foreign coun60
tries. Basic privacy protection measures still apply, but research subjects do not have to sign an authorization to allow
61
access to their PHI.
Duke seems to approach the situation cautiously by explaining that there is debate about HIPAA’s application abroad
62
while noting the importance of privacy. Despite requiring researchers to provide equivalent protections to research subjects
abroad as they would to research subjects in the United States,
both Duke and Johns Hopkins allow waivers from general
63
HIPAA requirements. In contrast, UCLA denies that HIPAA
64
applies at all. Universities are hubs of knowledge and are often leaders in research. These patchwork recommendations
suggest that HHS guidance is necessary and important to ensuring the universal, standardized application of human subject protections.
3. Standards of Care in Research
Standards of care in research represent the degree of care
a “reasonable” and “prudent” researcher and research organiza65
tion must exercise. These standards are meant to protect human subjects research participants from abuse. Contemporary
human subjects protections began in 1947 with the adoption of
the Nuremberg Code, a set of standards developed by the Nuremberg tribunal to judge Nazi experimentation on individuals
66
during World War II. This Code provided the basic principles
that led to similar recommendations from the World Medical
59. Id.
60. HIPAA Frequently Asked Questions, UCLA OFF. OF THE HUM. RES.
PROT. PROGRAM, http://ora.research.ucla.edu/OHRPP/Pages/HIPAAFAQ.aspx
(last visited Apr. 8, 2014).
61. Id.
62. DUKE UNIV. HEALTH SYS. HUM. RES. PROT. PROGRAM, supra note 5, at
1.
63. Id.; JOHNS HOPKINS MED., supra note 49.
64. UCLA OFF. OF THE HUM. RES. PROT. PROGRAM, supra note 60.
65. Peter Moffett & Gregory Moore, The Standard of Care: Legal History
and Definitions: The Bad and Good News, 12(1) W.J. EMERGENCY MED. 109,
109 (2011).
66. 45 CFR 46-FAQs, HHS.GOV, http://answers.hhs.gov/ohrp/categories/
1562 (last visited Apr. 8, 2014).
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Association in the 1964 Declaration of Helsinki. Following
several publicized abuses by U.S. researchers, the U.S. government passed the National Research Act in 1974 covering
human subjects research and created the National Commission
for the Protection of Human Subjects of Biomedical and Behav68
ioral Research (“Commission”). The Commission produced the
Belmont Report, which provided three ethical guiding princi69
ples for research: respect for persons, beneficence, and justice.
70
The Belmont Report led to the adoption of federal guidelines.
The “Common Rule” represents the federal policy for the
protection of human subjects research that has been adopted by
71
several federal government agencies. It requires that
When research covered by this policy takes place in foreign countries,
procedures normally followed in the foreign countries to protect human subjects may differ from those set forth in this policy. . . In these
circumstances, if a department or agency head determines that the
procedures prescribed by the institution afford protections that are at
least equivalent to those provided in this policy, the department or
agency head may approve the substitution of the foreign procedures
72
in lieu of the procedural requirements provided in this policy.

In recent years, the research community has debated the
standard of care owed to research subjects in developing coun73
tries. The Declaration of Helsinki was revised in 2000 to endorse the view that every trial participant, no matter where the
trial was located, is entitled to the “worldwide best standard of
74
care.” This decision suggests that a lower standard of care is
75
unethical. It violates researcher’s obligations to trial partici76
pants and creates a double standard for the rich and poor. Despite the Declaration’s language, many public, private, nation67. Id.
68. Id.
69. THE BELMONT REPORT: ETHICAL PRINCIPLES AND GUIDELINES FOR
THE PROTECTION OF HUMAN SUBJECTS OF RESEARCH, THE NAT’L COMM’N FOR
THE PROT. OF HUM. SUBJECTS OF BIOMEDICAL & BEHAVIORAL RES. (Apr. 18,
1979), available at http://www.hhs.gov/ohrp/policy/belmont.html.
70. Federal Policy for the Protection of Human Subjects (‘Common Rule’),
http://www.hhs.gov/ohrp/humansubjects/commonrule/index.html
HHS.GOV,
(last visited Apr. 8, 2014).
71. Id.
72. 45 C.F.R. § 46.101(h) (2013).
73. R K Lie et al., The Standard of Care Debate: The Declaration of Helsinki Versus the International Consensus Opinion, 30 J. MED. ETHICS 190, 190
(2004).
74. Id.
75. Id.
76. Id.

2386

MINNESOTA LAW REVIEW

[98:2375

al, and international groups have concluded that in some circumstances, it is ethical to use a different standard of care in
77
different countries. Standards of care address what is legally
required, but also encourage the research community to consider what ought to be required. This debate often discusses
standards in clinical therapies, but not the standards of protec78
tion for research participant information. Because privacy
standards of care abroad is a gray area in U.S. law, it is important to consider not only whether requiring HIPAA is feasible, but also whether failing to do so violates research ethics.
As clinical research moves beyond U.S. borders and guidelines remain vague, clinical researchers and research sponsors
must confront a set of moral concerns around their legal and
79
ethical requirements. Many universities and other covered entities conduct research overseas and admit their confusion in
80
whether HIPAA applies in those endeavors. In addition, the
concept of global health has come to the forefront in the last
decade as influenza and AIDS illustrate the importance of
global health initiatives and international cooperation and un81
derstanding. Finally, medical records are increasingly electronic. The ease of electronic transfer and collection of data
82
heightens privacy concerns. As overseas research increases, so
does the importance of resolving this confusion. A guidance
document should clarify that HIPAA applies to a covered entity
working in the United States and abroad, despite roadblocks to
implementation. Covered entities would then be on notice that
HIPAA’s protections apply outside the United States, giving all
research subjects a guaranteed level of protection for personal
and medical information.
Expanding HIPAA’s application faces barriers to imple83
mentation. HIPAA requirements add costs to research. Applying U.S. federal law in other countries raises issues of extraterritorial application of U.S. law and conflicts of law between
U.S. privacy laws and privacy laws that exist in the host coun84
try. Researchers may be concerned about translating an
77.
78.
79.
80.
81.
82.
83.
84.

Id.
See, e.g., id.
See Bova, supra note 5; Glickman et al., supra note 4.
See supra Part I.B.2.
See supra Part I.B.3.
See FURROW ET AL., supra note 2, at 259.
See infra Part II.A.2.
See infra Part II.A.1, II.A.3.
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American-based privacy theory in countries with different cultural values and languages, the effect of added requirements on
the progress of research, and practical issues of enforcing
85
HIPAA abroad. Part II explains these barriers and suggests
ways to mitigate them. A government decision expanding
HIPAA’s application will decrease uncertainty and expand an
improved standard of care concerning privacy to all persons
participating in research with U.S. covered entities, whether in
the United States or abroad.
II. LEGAL AND ETHICAL ANALYSIS OF THE
FEASIBILITY OF OVERSEAS APPLICATION OF U.S.
PRIVACY STANDARDS
The Secretary’s Advisory Committee on Human Subjects
Research asked for further guidance on HIPAA’s application
86
abroad. Part A presents potential barriers to expansion
abroad and how these barriers can be mitigated. Part B discusses the ethical implications of applying HIPAA overseas,
concluding that research ethics and standards of care require
implementation of privacy protections abroad.
A. BARRIERS TO COMPLIANCE WITH HIPAA AND MITIGATING
THOSE BARRIERS
The potential consequences of applying HIPAA abroad
should be considered and weighed against potential consequences of failing to issue guidance. The barriers to applying
HIPAA overseas include the extraterritorial application of U.S.
law, cost, conflicts of law, translation problems, and the potential for hindering research.
1. Extraterritorial Application of U.S. Law
Congress has the power to enforce its laws beyond the ter87
ritorial boundaries of the United States, but there is a presumption that federal legislation applies only within the Unit-

85. See infra Part II.A.4–5.
86. OFF. FOR HUM. RES. PROT., DEP’T OF HEALTH AND HUM. SERVS., supra
note 16.
87. The presumption against extraterritorial application of U.S. law may
be rebutted if it is clear that the law is intended to apply outside of the United
States. See Foley Bros. v. Filardo, 336 U.S. 281, 283 (1949) (noting that it is
not a question whether Congress has the power to extend the Eight Hour Law
to work performed in foreign countries).
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ed States. This presumption relies on the idea that most legis89
lation is meant to cover domestic rather than foreign issues.
Morrison v. National Australia Bank Ltd. suggests that this
90
presumption is difficult to circumvent. This may present a
significant barrier to the application of HIPAA abroad.
Several considerations may present an exception to the
presumption when it comes to HIPAA enforcement. If HHS
produces guidance explicitly indicating that HIPAA applies
91
abroad, the presumption can be rebutted. As research and
other U.S. endeavors become global, the need for extraterritori92
al application of U.S. laws becomes more apparent. The presumption against extraterritorial application can be overcome
with new guidance from HHS responding to this issue and clar93
ifying that HIPAA must apply abroad. This guidance docu88. Morrison v. Nat’l Austl. Bank Ltd., 561 U.S. 247. (2010).
89. See Smith v. United States, 507 U.S. 197, 204 (1993).
90. Morrison, 130 S. Ct. at 2877 (noting that unless Congress expressly
writes a law to the contrary, the presumption is that a law is meant to apply
only within the United States).
91. Foley Bros., 336 U.S. at 285 (“The canon of construction which teaches
that legislation of Congress, unless a contrary intent appears, is meant to apply only within the territorial jurisdiction of the United States . . . .”).
92. See, e.g., Trey Childress, Wal-Mart and the Foreign Corrupt Practices
Act, CONFLICTOFLAWS.NET (Apr. 24, 2012), http://conflictoflaws.net/2012/wal
-mart-and-the-foreign-corrupt-practices-act/.
93. Agencies often use alternative measures to explain policy preferences
than the traditional note and comment process as required by the Administrative Procedure Act. These include legal opinions from agency counsel; management policies; guidance documents; manuals; instruction memoranda; and
regulatory guidance letters. Sam Kalen, The Transformation of Modern Administrative Law: Changing Administrations and Environmental Guidance
Documents, 35 ECOLOGY L.Q. 657, 659–60 (2008). This provides the agency
with a flexible way to communicate with regulated parties. Jill E. Family,
Administrative Law through the Lens of Immigration Law, 64 ADMIN. L. REV.
565, 566 (2012). Guidance documents are official “‘statement[s] of general applicability and future effect, other than [regulations]’ that set forth ‘a policy on
a statutory, regulatory, or technical issue or an interpretation of a statutory or
regulatory issue.’” Sean Croston, The Petition Is Mightier than the Sword: Rediscovering an Old Weapon in the Battles over “Regulation Through Guidance,” 63 ADMIN. L. REV. 381, 382 (2011) (quoting Office of Management and
Budget, Final Bulletin for Agency Good Guidance Practices, 72 Fed. Reg. 3432,
3434 (Jan. 25, 2007)). Guidance documents may proclaim an agency’s general
policies and interpretations, but they cannot set forth binding legal requirements. They can be practically binding in the effect they have on how the
agency enforces the policy and the difficulty that ensues for regulated parties
to challenge the guidance. Id. The enforceability and ability to challenge guidance documents in court is beyond the scope of this Note, but given that this
would be an interpretation of current HIPAA regulations, it would likely fall
neatly into what a guidance document is meant to be. Id.
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ment would interpret the existing HIPAA regulations as applying overseas.
2. Cost of HIPAA Compliance
HIPAA has been called a fiscal bottleneck for biomedical
94
research. There were many concerns about cost at the outset
95
of HIPAA’s implementation. HIPAA’s implementation costs
include training staff on HIPAA compliance and bolstering security of information both in the physical sense and in the
96
technological arena. In addition, covered entities incur costs
in three direct ways: (1) creating new forms for patients regarding privacy practices, (2) appointing or hiring persons to be in
charge of HIPAA compliance, and (3) needing revisions in busi97
ness associate contracts. Indirect costs include time and ener98
gy spent in compliance. Finally, there are continual costs to
maintain HIPAA compliance by training and re-training employees and maintaining the systems for protecting privacy as
99
technology and systems change.
100
HIPAA has been a part of U.S. law for over a decade.
101
Startup costs for HIPAA compliance were significant. The
cost of maintaining compliance, however, has been less signifi102
cant than predicted, and the cost of noncompliance can be
94. Jocelyn Kaiser, Privacy Rule Creates Bottleneck for U.S. Biomedical
Researchers, 305 SCI. 168, 168 (2004).
95. See id.; Peter Kilbridge, The Cost of HIPAA Compliance, 348 NEW
ENG. J. MED. 1423, 1423 (2003).
96. Kilbridge, supra note 95, at 1423.
97. Id.
98. See Arthur R. Williams et al., HIPAA Costs and Patient Perceptions of
Privacy Safeguards at Mayo Clinic, 34(1) JOINT COMMISSION J. ON QUALITY &
PATIENT SAFETY 27, 30 (Jan. 2008).
99. Id.
100. See 45 C.F.R. § 160.103 (2013).
101. See Williams et al., supra note 98, at 30.
102. See id.; see also Peter A. Winn, Confidentiality in Cyberspace: The
HIPAA Privacy Rules and the Common Law, 33 RUTGERS L.J. 617, 679–80
(2002).
The most likely explanation of the increase incosts associated with
the implementation of the HIPAA Privacy Rules appears to be the
fact that, in recent years, many healthcare providers have invested
significant resources in increasingly accessible computerized health
information networks without maintaining appropriate safeguards to
protect medical information as the accessibility of health information
increased. As we have seen, traditional standards for confidentiality
that involved only modest costs when information was stored in
locked file cabinets, or in main frame computers, now present much
more difficult and expensive information management problems in
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high. Actors operating abroad could face monetary costs if HHS
decides to use the vagueness of the law to enforce HIPAA
103
abroad.
All covered entities in the United States should already be
in compliance, thus requiring their overseas researchers to
comply with HIPAA protocols should not significantly increase
104
costs. Some argue that HIPAA compliance would slow and
diminish research in the United States, but others see this re105
action as “alarmist.” Research in the United States has con106
tinued. Much of the infrastructure that allows for continued
compliance of covered entity researchers in the United States
107
could be used when those covered entities operate overseas.
The infrastructure of compliance is already familiar to most actors; therefore new cost of compliance barriers are foreseeable
and will not unfairly stunt research.
There are increasing financial consequences for noncompliance in the United States. In 2009, the maximum penal108
ty was increased from $25,000 to $1.5 million. A recent case
the context of vast national electronic health networks. Thus, the
high cost estimates associated with the HIPAA Privacy Rules appear
to be due simply to the exponential growth in the use of electronic
health information by the health care industry without a concomitant
investment in compliance with previously existing duties of confidentiality.
Id.
103. HITECH Act Enforcement Interim Final Rule, HHS.GOV, http://www
.hhs.gov/ocr/privacy/hipaa/administrative/enforcementrule/hitechenforcement
ifr.html (last visited Apr. 8, 2014) (noting a maximum penalty of $1.5 million
for violations).
104. While many were concerned with start-up costs, maintaining compliance has been less strenuous. See Williams et al., supra note 98, at 32 (noting
that “added into annual operating costs, and spread over the patient census,
the average privacy cost per patient visit ($0.90) and per patient ($4.00) appears modest . . . . [M]odest expense (cost) and improved patient information
are both achievable . . . .”). In addition, HIPAA might lead to cost saving in an
institution. See Jerry LaMartina, Cost vs. Benefits of HIPAA Is Unclear, but
Change in Procedures Is a Certainty, KAN. CITY BUS. J., May 19, 2002,
http://www.bizjournals.com/kansascity/stories/2002/05/20/focus6.html
(“Standardized electronic transactions could save businesses an estimated $10
billion to $15 billion during 10 years . . . .”). It could logically follow that maintaining compliance overseas would not create a significant increase in costs.
105. See George J. Annas, HIPAA Regulations—A New Era of MedicalRecord Privacy?, 348 NEW ENG. J. MED. 1486, 1489 (2003).
106. See Trends, Charts, and Maps, CLINICALTRIALS.GOV (Nov. 9, 2012),
http://www.clinicaltrials.gov/ct2/resources/trends (stating that there are currently 162,059 clinical trials registered on clinicaltrials.gov in the U.S.).
107. See supra Part I.B.2.
108. Amanda McGrory-Dixon, HHS Toughens HIPAA Violation Penalties,
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involving a HIPAA violation by a former UCLA employee was
109
the first to lead to incarceration. In that case, a UCLA researcher was sentenced to jail time for looking at patient rec110
ords he did not have the authorization to view. This signals
the importance of privacy in health records. While it is unclear
whether HIPAA applies, if HHS were to interpret the language
of HIPAA as reaching covered entities abroad, the stakes are
high for noncompliance.
3. Conflicts of Law
Several researchers have concluded that HIPAA must not
apply internationally because there would be serious conflict of
111
law issues. These researchers suggest that the foreign laws of
the country hosting the researchers would trump the applica112
tion of HIPAA. For example, the European Union (EU) has
113
its own law protecting privacy of personal data. This law applies generally to all EU members, requiring them to protect
the “right to privacy with respect to the processing of personal
data” and restrict the flow of information between member
114
states.
Comparing the EU law with HIPAA suggests that conflicts
of law may be a barrier to applying HIPAA in other countries
because the EU privacy law has some significant differences
from the HIPAA privacy rule. For example, the term “personal
115
data” is broader than the definition of PHI under HIPAA.
The EU Directive defines personal data to include any infor116
mation related to an identified or identifiable natural person.
In addition, the definition of processing is also broadly defined
BENEFITSPRO (Apr. 9, 2013), http://www.benefitspro.com/2013/04/09/hhs
-toughens-hipaa-violation-penalties; see also HITECH Act Enforcement Interim Final Rule, supra note 103.
109. Pamela Lewis Dolan, HIPAA Violation Leads to Jail Time,
AMEDNEWS.COM, June 7, 2010, http://www.amednews.com/article/20100607/
business/306079969/6/.
110. Id.
111. Secretary’s Advisory Committee on Human Research Protections Appendix H, supra note 16.
112. Id.
113. See, e.g., European Parliament and the Council of the European Union, Directive 95/46/EC of the European Parliament and of the Council of 24
October 1995, 1995 O.J. (L 281) 31 (Nov. 23, 1995), available at http://eur
-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31995L0046:en:HTML.
114. Id. at art. 1.
115. Id.
116. Id. at art., 2 § a.
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to mean any operations on personal data including collection,
recording, storage, use, disclosure, or destruction beyond the
117
disclosure and misuse provisions of HIPAA. The entity controlling this data is called a “controller” which may at first
118
sound like a covered entity. However, the EU Directive’s definition of “controller” is not limited to healthcare providers and
119
business associates considered by HIPAA. Finally, in order
for a controller to transfer data to a third country, that third
120
country must ensure an “adequate level of protection,” and
the EU has determined that the United States does not fulfill
121
this criterion. To remedy this, the U.S. Department of Commerce worked with the European Commission to develop a safe
harbor provision where U.S. organizations can be deemed to
122
have an adequate level of protection. Differing national privacy requirements may make ensuring HIPAA compliance
more complicated when researching outside of the United
States
Despite the potential for conflicts of law, this does not automatically preclude HIPAA’s application abroad. Researchers
may work with their IRB to come up with a solution when
123
there is more than one applicable law. In addition, if a research institution or covered entity does a lot of research in a
region, they may be able to determine what a combination of
HIPAA with the local privacy laws requires, and use that for
124
every study done under the name of that covered entity.
HIPAA was designed to minimize conflicts of law among the
125
states. Covered entities or states may require more protec117. Id. at art. 2, § b.
118. See id.
119. Id. at art. 2, § d. A controller includes any natural or artificial person,
public authority, agency, or anything else that processes personal data.
120. Id. at art. 25, § 1.
121. See Commission Decisions on the Adequacy of the Protection of Personal Data in Third Countries, EUROPEAN COMMISSION (2011), http://ec.europa
.eu/justice/data-protection/document/international-transfers/adequacy/index_
en.htm (last visited Apr. 8, 2014).
122. Brunts et al., supra note 18, at 20.
123. Basic HHS Policy for Protection of Human Subjects, 45 C.F.R.
§ 46.101 (2013). Institutional Review Boards must approve must approve proposed non-exempt research before beginning research involving human subjects.
124. Brunts et al., supra note 18, at 20.
125. HIPAA Frequent Questions “How Does the HIPAA Privacy Rule Reduce The Potential for Conflict With State Laws?,” HHS.GOV, http://www
.hhs.gov/hipaafaq/state/401.html (last visited Apr. 8, 2014).
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tions for individually identifiable health information or create
126
greater privacy rights. HIPAA is designed to be a floor, mak127
ing it a baseline of protections from which to build upon. If
the covered entity is working in a country that requires greater
protections than HIPAA, they will have to follow that country’s
laws. But if the country has a lower privacy standard or none
at all, then the covered entity should provide HIPAA’s basic
level of protections, regardless of the research participant’s citizenship and location of the trial.
4. Translation of an American-Based Theory of Privacy
Differing cultural norms around privacy and human rights
may generate ethical incongruence. Translating HIPAA rights
and requirements to a culture that may not share the same
concepts of privacy constitutes a potential barrier to implemen128
tation. This has given rise to discourse centering on the validity of applying an American-based theory of research ethics in a
129
different culture, and confronting the potential of “medical130
ethical imperialism.” The application of an American-based
theory of privacy overseas through HIPAA may be challenged
131
as culturally inappropriate.
In contrast to the idea that privacy concepts embedded into
western culture and codified in HIPAA are difficult or nontranslatable in international settings is the issue of practicing
double standards for U.S.-based research and research
132
abroad. Translational issues and cultural differences are a
133
traditional problem in all parts of international research but
they need not hinder research progress. Cultural divides may
126. Id.
127. Id.
128. See Salla Sariola & Bob Simpson, Theorising the ‘Human Subject’ in
Biomedical Research: International Clinical Trials and Bioethics Discourses in
Contemporary Sri Lanka, 73 SOC. SCI. & MED. 515, 516 (2011) (suggesting
that the philosophies underpinning bioethics are reflective of Anglo-American
rather than universal values).
129. Carel B. IJsselmuiden & Ruth Faden, Research and Informed Consent
in Africa—Another Look, 326 NEW ENG. J. MED. 830, 830 (1992).
130. Id. Medical ethical imperialism involves the imposition of solutions
culturally appropriate for one society onto another society assuming that those
solutions represent moral absolutes. See Charles F. Gilks, Ethical Imperialism, 322 NEW ENG. J. MED. 200, 200 (1990).
131. IJsselmuiden & Faden, supra note 129, at 830.
132. Id.
133. S.R. Benatar, Reflections and Recommendations on Research Ethics in
Developing Countries, 54 SOC. SCI. & MED. 1131, 1135 (2002).
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be bridged if a researcher invests skill, time and interest in
134
breaking down those walls. For example, it has been noted
that in Uganda the western concept of informed consent has
faced the problems of (i) socioeconomic inequalities between researchers and subjects, which results in subjects feeling they
have no choice when asked to participate in a research study;
(ii) colonialism, which instills divides in power and trust between researchers and subjects; and (iii) erosion of the Ugandan health care system, which left many with a suspicion that
135
HIV was brought to Africa by foreigners. Researchers should
be informed of these things before attempting to achieve required informed consent of research participants. When discussing privacy, anthropologists indicate that it is typical of African culture that individuals perceive themselves as
136
extensions of the family. They see themselves as an intermediaries between ancestors and future generations, not as individual persons in their own right who makes decisions only for
137
themselves. This might mean that privacy, as well as informed consent, cannot be translated to a culture that makes
decisions as a community. It is important to understand these
barriers before beginning research. Anthropologic literature involving local health care authorities and the continued assis138
tance of an ethics committee is useful.
In addition, literature on doctor-patient and scientistsubject interactions in western countries notes that differences
in culture and class between the two limits the effectiveness of
communication, but no one suggests that there be varied
139
standards based on such differences. While privacy is not
necessarily defined the same across all cultures, fears of cultural imperialism may be allayed by making it clear that only
U.S. firms are expected to adhere to HIPAA guidelines. HIPAA
was designed as a base of privacy protection able to protect persons regardless of their differences, and moving research
abroad should not change this standard.
5. Increasing Requirements and the Slowing of Research
Complying with HIPAA may require added time and re134.
135.
136.
137.
138.
139.

Id.
Id. at 1134.
See IJsselmuiden & Faden, supra note 129, at 830.
See id.
See Benatar, supra note 133, at 1135, 1137.
See id.
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sources that would slow the pace of research in clinical trials
140
abroad. HIPAA would require that resources and time be
spent explaining privacy rights, training researchers and clinical staff on HIPAA, and setting up safeguards to protect priva141
cy of research subjects.
The need for data can be immediate. In some cases, it is
necessary to give research speed a high priority. For example,
data on HIV transmission, hepatitis B, or multi-drug-resistant
tuberculosis is critical and time sensitive to those infected and
142
to those who may become infected. Adding these regulatory
143
requirements might hinder the research and slow progress in
the effort to end the global epidemics of these potentially fatal
illnesses.
There are many urgent health needs, and many of these
are rampant in developing countries outside of the United
144
States.
The question ought not be whether this research
needs to be done in haste, but whether that urgency warrants
reducing ethical standards because of the added time, expense,
and effort that increasing privacy protections would require.
The pace at which research findings are actually implemented in the form of new drugs, technologies, and vaccines
145
does not support reduced ethical standards. For example, the
hepatitis B vaccine was approved for use in the United States
146
in the late 1970s. Replicating these trials in Africa was important because there can be different responses in different
147
groups. The argument that the urgency of the research findings was so great as to prevent the researchers from complying
with ethical standards required in the United States is unsupported because even if the vaccine was effective it was unlikely
140. See IJsselmuiden & Faden, supra note 129, at 830.
141. See supra Part I.A (describing the requirements of HIPAA compliance).
142. See, e.g., Press Release, AVAC, Continued Investment in HIV Prevention Research Can Speed Development of New Options To Help End the AIDS
Epidemic (June 30, 2013), available at http://online.wsj.com/article/PR-CO
-20130630-900440.html (explaining the urgent need for research in this area).
143. Id.
144. The Top 10 Global Health Issues To Watch in 2013,
INTRAHEALTH.ORG, (Jan. 15, 2013), available at http://www.intrahealth.org/
page/the-top-10-global-health-issues-to-watch-in-2013.
145. See IJsselmuiden & Faden, supra note 129, at 830.
146. See Hepatitis B, CTRS. FOR DISEASE CONTROL AND PREVENTION (May
7, 2012), http://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html.
147. See id. (discussing how serologic markers of hepatitis B can vary depending on whether the infection is acute or chronic).
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to be rapidly used and disbursed following this positive find148
ing. The inevitable lag between research findings and action
cripples the argument for decreasing ethical standards in the
149
face of urgency for results.
The debate over whether HIPAA applies to covered entities
working abroad is exacerbated by the lack of specific guidance
150
from HHS. In addition, institutions of higher education that
are often leaders in the research field supply a varied patchwork of conclusions regarding HIPAA’s implications in interna151
tional research. Potential consequences of applying HIPAA
abroad include issues of extraterritorial application of U.S. law,
added costs, conflicts of law, and translation of privacy to different cultures. While these are not to be ignored, they can be
mitigated with a flexible approach. Moreover, the consequences
of not applying HIPAA are grave.
B. ETHICAL ANALYSIS OF PRIVACY STANDARDS
Costs of not issuing guidance to require compliance with
HIPAA overseas include both monetary and ethical considerations. This section argues that implementing HIPAA abroad is
an ethically necessary solution because it would significantly
add to the propriety of U.S. researchers working abroad, and
that HIPPA is a baseline of privacy protections that ought to be
guaranteed by every covered entity.
1. Past Abuses in Standards of Care and Current Standards of
Care in Research Highlight the Need for Equity and the
Importance of Privacy for All Persons
The AZT trials conducted in the 1990’s in Africa are a
blemish on U.S. research history in the context of standard of
care issues. These trials, conducted in Africa, involved research
on antiretrovirals in preventing transmission of HIV from
152
mother to child. Although there were established therapies,
148. See Hilton Whittle et al., Observational Study of Vaccine Efficacy 14
Years After the Trial Vaccination in Gambian Children, 325 BMJ 7364 (Sept.
4, 2002), available at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC124550/.
149. See id.
150. See Secretary’s Advisory Committee on Human Research Protections
Appendix H, supra note 16.
151. See DUKE UNIV. HEALTH SYS. HUM. RES. PROT. PROGRAM, supra note
5; JOHNS HOPKINS MED., supra note 49; UCLA OFF. OF THE HUM. RES. PROT.
PROGRAM, supra note 60; YALE UNIV. OFF. OF RES. ADMIN., supra note 58.
152. See Peter Lurie & Sidney M. Wolfe, Unethical Trials of Interventions
To Reduce Perinatal Transmission of the Human Immunodeficiency Virus in
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153

there was a placebo control arm to the study. The placebo
control arm was defended by researchers, “arguing that the
subjects are treated at least according to the standard of care in
these countries, which consists of unproven regimens or no
154
treatment at all.” Using the host country’s standard of care
(which may be no standard at all, as in this case), led to outcry
155
against the study’s design.
In August 2011, the families of children who died during a
meningitis drug trial in Nigeria received their first payments
156
following a settlement with the sponsor. “[Eleven] children
died in the trial: five after taking the drug Trovan and six after
taking an older antibiotic [that was] used for comparison in the
clinical trial. Others suffered blindness, deafness and brain
157
damage.”
A panel of Nigerian medical experts concluded that
the study violated international law by testing an unapproved
drug on children and failing to obtain authorization from the
158
Nigerian government for the trial. Criticism remains that research moves overseas to avoid U.S. regulatory protections and
159
capitalize on less demanding requirements abroad, and the
President’s Commission on Bioethics has stated that there is
160
still much room for improvement to protect research subjects.
The Common Rule states that to gain approval from the
IRB there must be “adequate provisions to protect the privacy
161
of subjects and to maintain the confidentiality of data.” Privacy protections must be at least equivalent for those governDeveloping Countries, 337 NEW ENG. J. MED. 853 (1997).
153. Id. at 855.
154. Id.
155. Id. (arguing that any acceptance of the standard of care that does not
conform to the standard in the sponsoring country leads to a “double standard”
in research).
156. Donald G. McNeil, Jr., Nigerians Receive First Payments for Children
Who Died in 1996 Meningitis Trial, N.Y. TIMES, Aug. 11, 2011, http://www
.nytimes.com/2011/08/12/world/africa/12nigeria.html.
157. Id.
158. Joe Stephens, Panel Faults Pfizer in ‘96 Clinical Trial in Nigeria,
WASH. POST, May 7, 2006, http://www.washingtonpost.com/wp-dyn/content/
article/2006/05/06/AR2006050601338.html.
159. See Stacey B. Lee, Informed Consent: Enforcing Pharmaceutical Companies’ Obligations Abroad, 12(1) HEALTH & HUM. RTS.: INT’L J. 15, 15 (2010),
available at http://www.hhrjournal.org/2013/08/26/informed-consent-enforcing
-pharmaceutical-companies-obligations-abroad/.
160. See President’s Commission Releases Report on Human Subjects Protection, BIOETHICS.GOV, http://bioethics.gov/node/559 (last visited Apr. 8,
2014). This includes greater transparency and accountability. Id.
161. 45 C.F.R. § 46.111(a)(7) (2013).
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ment agencies that have adopted the Common Rule. The Declaration of Helsinki, requires that
The right of research subjects to safeguard their integrity must always be respected. Every precaution should be taken to respect the
privacy of the subject, the confidentiality of the patient’s information
and to minimize the impact of the study on the subject’s physical and
162
mental integrity and on the personality of the subject.

These documents suggest that privacy is a contemplated
protection for research subjects both in the United States and
abroad. Yet, the U.S. government has not taken steps to explicitly state that HIPAA is required by all U.S. covered entities
working overseas and the varied understanding of the nation’s
research universities illustrates that this question must be addressed. These examples indicate that the United States has
faced standards of care issues in the past and has favored expansion of rights of human subjects. This approach of expanding rights should be furthered in the realm of privacy by adopting HIPAA’s standards that give practical steps to improve
privacy protections for all human subjects.
2. Lowered Standards of Care Decrease the Propriety of U.S.
Researchers and Hinder International Research
The consequences of reducing ethical standards are great.
International noncompliance could lead to the loss of patient,
research subject, or public’s trust that HIPAA aimed to
163
achieve. Surveys and evidence suggest that patients value
HIPAA privacy regulations and the rights that come with
164
them. Potential costs of ethical transgressions in standards of
care abroad include loss of integrity in research and interna165
tional relations. U.S. health work abroad has seen major ethical transgressions that have damaged the reputation of U.S.
sponsored initiatives. For example, following the false hepatitis
vaccination scheme to attempt to find Osama Bin Laden, a
campaign against the polio vaccine and those aid workers who

162. World Medical Association Declaration of Helsinki, Bulletin of the
World Health Org. 374 (2001), available at http://www.who.int/bulletin/
archives/79(4)373.pdf.
163. See Annas, supra note 105, at 1486 (arguing that the public policy rational for protection of privacy is that patients will be less likely to disclose details necessary for proper medical care if they do not trust their physicians to
keep the information secret, and HIPAA is a way to ensure these principles in
the electronic age).
164. See Williams et al., supra note 98, at 30.
165. See Lurie & Wolfe, supra note 152, at 855.
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166

administer it has been launched. Unarmed volunteers, all
over Pakistan, Somalia, and Afghanistan are being targeted for
167
assassinations and their important vaccines being refused.
This same distrust of western medicine and vaccination result168
ed following a research trial of a meningitis drug.
Standards of care for research subjects can vary, and the
government has set guidelines in the past to address these is169
sues. Privacy is now a part of the accepted standard of care
and should be recognized as such. Upsetting the public or research community with poor research practices can end a project, waste money for the host organization, and damage the integrity of the research organization as a whole. It is in the best
interests of researchers and research organizations alike to follow HIPAA standards when overseas.
3. The Potential Costs to Research Participants in Studies
Using Lower Privacy Standards is Great
Beyond the financial costs and potential standard of care
conflicts is the human cost of not applying HIPAA overseas. Before HIPAA was written, the American medical community
witnessed unauthorized use of medical records for blackmail,
170
harassment, job exclusion, and discrediting of persons.
HIPAA was enacted in 1996 to address the public’s fears as
electronic medical records increased the threat of these inva171
sions of privacy. These fears are just as real in any country.
Research could implicate a particularly stigmatized subject like
HIV status, or it may involve private medical histories. Leaving
people vulnerable to abuse is the human cost of noncompliance. There should be an obligation to protect information collected about medical histories, diagnoses, and other
PHI so that this information can’t be used to harm participants
or their families, whether they are U.S. citizens or not.
166. See Emma Green, Five Global Health Concerns, THE ATLANTIC, Oct.
5, 2013, http://www.theatlantic.com/events/archive/2013/10/five-global-health
-concerns/280304/.
167. Id.
168. See McNeil, supra note 156.
169. See Part II.B.1.
170. The story of Thomas Eagleton is a good example in which his medical
records were used to discredit his campaign as Vice President. See The Thomas Eagleton Affair Haunts Candidates Today, NPR (Aug. 4, 2012),
http://www.npr.org/2012/08/04/157670201/the-thomas-eagleton-affair-haunts
-candidates-today; see also supra notes 2–4.
171. See Choi et al., supra note 22, at 58.
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Research subjects often do not have any say in determining
standards of care. In worst-case scenarios, standards are determined by the financial limitations that these research subjects live with because their government cannot afford the high
prices set by drug and device companies and medical indus172
try. Standards of care should reflect the laws of the entity’s
home country, not the power asymmetries of the subject coun173
try. While our laws may not specifically require the application of HIPAA abroad, the spirit of the laws we do have, including the Common Rule, and the ethical transgressions that led
to the creation of international standards of care, do require the
application of HIPAA abroad.
III. ISSUING GUIDANCE TO IMPLEMENT HIPAA ABROAD
Universities and other research organizations are unsure
174
of the privacy requirements for studies conducted overseas.
Standards of care in international research are a constantly
developing area and privacy is becoming part of that standard,
175
ripe for recognition. To require HIPAA compliance internationally, HHS must issue guidance. Part A explains what guidance from HHS should look like. Part B discusses overcoming
barriers to implementing HIPAA abroad. Part C argues that
privacy is a fundamental right, and that basic privacy protections for research subjects is part of that right.
A. WHAT GUIDANCE FROM HHS OUGHT TO LOOK LIKE
HHS must issue guidance clarifying that the scope of
HIPAA reaches covered entities working overseas. This guidance should state:
HIPAA privacy protections apply to covered entities working abroad. All covered entities must comply with the following
basic privacy protections:
1. Covered entities must have a set of policies in place for
176
compliance with HIPAA.
2. There must be a system of training of covered entity

172. See Lurie & Wolfe, supra note 152, at 855.
173. See Marcia Angell, The Ethics of Clinical Research in the Third World,
337 N. ENG. J. MED. 847, 848 (1997).
174. See supra Part I.B.2.
175. See Lie et al., supra note 73, at 190.
176. See, e.g., 45 C.F.R. § 164.530(i)(1) (2013) (describing policies and procedures).
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staff on compliance and on the importance of privacy.
3. International patients or research participants should
receive notice of privacy practices in their own language, so
178
they know how their information might be used or disclosed.
4. Covered entities must have appropriate administrative,
technical, and physical safeguards to protect against unauthor179
ized disclosures.
5. Covered entities should work with their IRB to meet
these basics and adapt them to their host country and population’s needs.
This guidance document would allow flexibility in working
with the IRB to reach acceptable standards of care and privacy
policies without sacrificing HIPAA’s requirements and research
participants’ right to privacy. It would also mean that all covered entities would clearly know that HIPAA applies abroad
and that they are required to consider and protect human subjects’ privacy in the United States and abroad.
The Secretary’s Advisory Committee on Human Research
Protections has suggested that IRB alterations of HIPAA’s authorization requirements, which involve research subjects giving permission for the use of their information in the study,
180
might be sought. This would be a “boiled down” version of the
181
elements of authorization. The approach from universities in
182
response to this debate is a good example of potential compromise. IRBs and covered entities can work together to determine how to best protect PHI with the baseline requirements of
HIPAA as a framework. HIPAA has standards but is also a law
that allows for flexibility for covered entities to take into account their costs, size, and level of risk for security breach of
183
PHI. A covered entity may use any security measures, as long
as they reasonably and appropriately implement HIPAA
184
standards. This should make it easier for covered entities to
work with IRB’s to implement HIPAA and protect the privacy
177. See, e.g., id. § 164.530(b)(1) (describing standards for training).
178. See, e.g., id. § 164.520 (outlining notice of privacy practices for protected information).
179. See, e.g., id. § 164.530(c)(1) (describing standards for safeguards).
180. See Secretary’s Advisory Committee on Human Research Protections
Appendix H, supra note 16.
181. Id.
182. See supra Part I.B.2.
183. See 45 C.F.R. § 164.306(b).
184. Id.
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of all persons in research or treatment while also taking into
account the differing needs of researchers and populations.
Basic HIPAA protections for patient or research participants’ health histories should be maintained as researchers
work with their IRB to determine which safeguards are necessary given the nature of the research. HHS guidance should be
rigid in its principle of privacy protection for research subjects,
but flexible in building upon HIPAA’s baseline protections, a
process through which a research entity and IRB may find solutions to the varying issues involved in international research.
With this clarifying guidance document, covered entities would
not have to deal with uncertainty as to whether protections apply abroad and those research subjects with whom they work
would be guaranteed protection of private personal and medical
185
information.
Although this guidance would simply extend basic privacy
protections to all persons participating in research with U.S.
covered entities, the potential barriers to implementation discussed in Part II.A should be considered. These include extraterritorial application of U.S. law, costs associated with compliance, conflicts of law, translational issues, and the effect of the
regulation on the pace of research. In addition, practical concerns including who will enforce the law and how research participants will be able to understand the law are important.
B. OVERCOMING BARRIERS TO APPLYING HIPAA OVERSEAS
As explained in Part II.A, there are several barriers to implementing HIPAA abroad, but with planning and use of current HIPAA infrastructure, these barriers are surmountable.
Extraterritorial application of U.S. law issues can be avoided
quickly, if HHS issues guidance that HIPAA should apply
186
abroad. Additional costs to research organizations for imple187
menting HIPAA overseas is a legitimate concern. Yet, HIPAA
188
has been a part of U.S. law for over a decade, and every covered entity in the United States should already be in compliance. Requiring overseas researchers to follow the same proto185. See Choi et al., supra note 22, at 58.
186. See Foley Bros. v. Filardo, 336 U.S. 281, 283 (1949) (noting that it is
not a question whether Congress has the power to extend the Eight Hour Law
to work performed in foreign countries).
187. See Kilbridge, supra note 95, at 1423.
188. Congress enacted HIPAA in 1996. See The Health Insurance Portability and Accountability Act of 1996, Pub. L. 104–91, 110 Stat. 1936.
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189

col should not overwhelm those organizations.
Conflicts of law may arise when applying a U.S. standard
overseas, but HIPAA is designed to be a floor and a baseline of
190
protections from which to build up. If a covered entity is
working in a country that requires more than HIPAA, they will
have to follow that country’s laws, but if the country has a less
thorough privacy rule or none at all, then the covered entity
should provide this basic level of protection, regardless of citizenship. Researchers may work with their IRB to come up with
the privacy plan to both adequately protect participant privacy
191
and comply with all laws.
Privacy concepts important to a western culture and codified in HIPAA may not be effective in international settings,
but practicing double standards for U.S.-based research and re192
search abroad is not the solution. Translational issues and
cultural differences are a traditional problem in all interna193
tional research, but if a researcher invests skill, time and interest in understanding those differences there should not be a
194
conflict. HIPAA was designed as a base of privacy protection
without regard to differences, and where privacy translation is
an issue, a researcher may work with their IRB to find a solu195
tion to comply with HIPAA without insulting local culture.
HIPAA compliance will require added time and resources
196
that may slow the pace of research in overseas clinical trials.
But reducing ethical standards to potentially increase the pace
of discovery would not directly lead to faster implementation of
197
new drugs, technologies, or vaccines. While reduced pace is a
risk, it does not warrant a decreased standard of care.
Finally, in addition to the issues with HIPAA application
discussed above are the practical difficulties in beginning to require HIPAA compliance overseas. The OCR at HHS may audit
a covered entity, but they also accept complaints from anyone
189. See supra note 104.
190. See LaMartina, supra note 104.
191. Protection of Human Subjects, 45 C.F.R. § 46.101 (2013). Institutional
Review Boards must approve must approve proposed non-exempt research before beginning research involving human subjects. Id.
192. See IJsselmuiden & Faden, supra note 129, at 830.
193. See Benatar, supra note 133, at 1134–35.
194. See id. at 1134–36.
195. See id. at 1134.
196. See, e.g., IJsselmuiden & Faden, supra note 129, at 831–33 (discussing
researchers’ obligations when conducting research in developing countries).
197. See id. at 830.
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who feels their privacy rights have been violated. There is a
main office in Washington, D.C., and several smaller investiga199
tor offices throughout the country. The current complaint
process is focused on persons in the United States, and its expansion may prove difficult. Yet with proper planning these
practical difficulties can be avoided.
OCR works to achieve voluntary compliance through cor200
rective actions and agreements with covered entities. This
collaboration between covered entities and OCR would likely
continue. The enforcement process is largely complaint driv201
202
en. As there is no private right of action, international research subjects or persons being treated abroad would not be
able to sue over a HIPAA violation, but they could file com203
plaints with OCR. OCR would work towards voluntary compliance with the covered entity to improve their privacy protec204
tions globally. Complaints may be submitted electronically or
in writing, and the OCR offices are adamant that anyone may
205
file a complaint, including noncitizens. In addition, while it
may be more difficult for persons outside the United States to
206
learn about the OCR process, it is not impossible. The infor207
mation is on the internet and available globally, and covered
entities would be required to explain these options as part of
their privacy policy provided to each research participant before beginning a study. Resource limits for researchers and research subjects, including reduced access to computers or the
internet, present a problem to the proper filing of complaints.
Self-enforcement and voluntary compliance will be even more
important in the context of research abroad. In addition, the
IRB and the Ethics Committee should play a role in ensuring
208
privacy protections and HIPAA compliance.
198. See Health Information Privacy: How To File a Complaint, HHS.GOV,
http://www.hhs.gov/ocr/privacy/hipaa/complaints/index.html (last visited Apr.
8, 2014).
199. Id.
200. See FURROW ET AL., supra note 2, at 282.
201. Id.
202. Id.
203. See Health Information Privacy: How To File a Complaint, supra note
198.
204. See FURROW ET AL., supra note 2, at 282.
205. Id.
206. See id.
207. Id.
208. See Benatar, supra note 133, at 1137 (arguing the importance of ethics
committees).
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C. PRIVACY AS A FUNDAMENTAL HUMAN RIGHT
In the 1890s, future Supreme Court Justice Louis Brandeis
argued that privacy had become essential to the individual, but
“modern enterprise and invention have, through invasions upon his privacy, subjected him to mental pain and distress, far
209
greater than could be inflicted by mere bodily injury.” As personal information becomes more readily available and valua210
ble, many are afraid that individual privacy is an unachieva211
ble goal. Even though privacy seems to be slipping away, it is
212
a fundamental human right. It is recognized by the Universal
213
214
Declaration of Human Rights, the Declaration of Helsinki,
215
and the International Covenant on Civil and Political Rights.
Privacy in health is essential to human dignity. The paradox in
current health care privacy practices is that U.S. researchers
may either disregard the dignities of our neighbors for scientific
gain, or risk accusations of cultural imperialism by granting
them the same rights we expect within our own borders. The
fluidity of information in the modern age has diminished the
rigidity of borders and the function of laws that cover only that
information within them. Privacy may be more difficult to
achieve, but there remains a moral imperative to enforce privacy in health as a basic human right by guaranteeing protection
of private information in research in all cases. Expanding
HIPAA to cover international research would achieve this goal.

209. Samuel D. Warren & Louis D. Brandeis, The Right to Privacy, 4 HARV.
L. REV. 193, 196 (1890).
210. PHI covers any personal information, including identity indicators
which can be valuable. See 45 C.F.R. § 160.103 (2013).
211. See, e.g., Jean-Louis Gassée, NSA Files Show Privacy Does Not Exist,
THEGUARDIAN.COM (Aug. 5, 2013), http://www.theguardian.com/technology/
blog/2013/aug/05/nsa-privacy-surveillance-monday-note.
212. See, e.g., Universal Declaration of Human Rights, G.A. Res. 217 (III)
A, U.N. Doc. A/RES/217(III) (Dec. 10, 1948) ( “No one should be subjected to
arbitrary interference with his privacy. . . .”); see also Dominic Rushe, UN Advances Surveillance Resolution Reaffirming ‘Human Right to Privacy,’
THEGUARDIAN.COM (Nov. 26, 2013), http://www.theguardian.com/world/
2013/nov/26/un-surveillance-resolution-human-right-privacy.
213. Universal Declaration of Human Rights, supra note 212.
214. World Medical Association Declaration of Helsinki, Bulletin of the
World Health Org. 374 (2001), available at http://www.who.int/bulletin/
archives/79(4)373.pdf.
215. International Covenant on Civil and Political Rights, Dec. 16, 1966, S.
Exec. Rep. 102-23, 999 U.N.T.S. 171.
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CONCLUSION
The expansion of electronic record keeping, the ease of information sharing, and the rise of clinical trials overseas has
highlighted the importance of privacy of health information and
the need for heightened scrutiny of privacy practices of U.S. en216
tities working abroad. Privacy has developed into a widely
217
recognized basic right. Parallel to these increased concerns
over privacy is the international expansion of clinical research
218
by U.S. organizations. Regulations to protect this right have
lagged behind the expansion of operations as globalization of
healthcare proceeds unabated.
While HIPAA requires basic privacy protections of health
219
information by all covered entities in the United States, when
those covered entities leave the United States., HIPAA may no
220
Interpretations vary widely—some believe
longer apply.
HIPAA does not apply abroad while others think it attaches to
221
covered entities regardless of where they work. This confusion contributes to an ineffective patchwork of privacy protec222
tions.
To achieve clarity, the basic protections guaranteed by
HIPAA should be part of the legal and ethical requirements for
research or treatment performed by U.S. covered entities both
in the United States. and internationally. While there are difficulties inherent in expanding HIPAA application overseas, these barriers are not insurmountable and the consequences of
failing to provide privacy protections can be great. The De216. FURROW ET AL., supra note 2, at 265.
217. Id. at 268–69 (suggesting that privacy is a value on which our society
is built, but it is also necessary for the effective delivery of care, and a breach
of health privacy can have implications beyond physical health including loss
of a job, alienation of family and friends, loss of health insurance, and public
humiliation).
218. See Glickman et al., supra note 4, at 816.
219. See Choi et al., supra note 22, at 58.
220. See Secretary’s Advisory Committee on Human Research Protections
Appendix H, supra note 16.
221. See id.
222. See, e.g., DUKE UNIV. HEALTH SYS. HUM. RES. PROT. PROGRAM, supra
note 5 (providing policies for international research to Duke investigators);
JOHNS HOPKINS MED., supra note 49 (describing John Hopkins’ standard
practices); UCLA OFF. OF THE HUM. RES. PROT. PROGRAM, supra note 60 (outlining HIPAA research); YALE UNIV. OFF. OF RES. ADMIN., supra note 58
(providing guidance on various rules, regulations, and polices specific to international research).
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partment of Health and Human Services must issue guidance
documents establishing that HIPAA’s requirements extend to
covered entities whether they are in the United States or
abroad. This guidance should reflect the basic ideals of HIPAA,
guaranteeing protection of patient information, including physical and technical safeguards, as well as organizational policies
and staff training, while allowing for flexibility to work with
their IRB to accommodate the needs of research teams and research populations. With this guidance document, covered entities would not have to deal with uncertainty as to whether protections apply abroad, and those research subjects they work
with would be guaranteed a level of protection for personal and
medical information in an increasingly global world with graver
consequences for breaches of privacy.

